Govt mulls FDI policy relaxation in medical devices sector

Image
Press Trust of India New Delhi
Last Updated : Oct 12 2014 | 10:39 AM IST
The government is looking at relaxing FDI policy for the cash-starved medical devices sector to attract more investments and boost domestic manufacturing.
Inter-ministerial consultations are on to liberalise the foreign direct investment policy for the sector "which badly needs foreign investment", sources said.
Besides the Commerce and Industry Ministry, the Finance Ministry, the Health and Family Welfare Ministry and the Department of Pharmaceuticals are involved in the consultations.
FDI in the sector is permitted through the government- approval route and the industry has been demanding that it be put under the automatic route, they said.
"India badly needs FDI in medical devices and equipment sector. The industry is not modern and there is no threat of mergers and acquisitions from multi-national firms as domestic companies are not big unlike drug firms. So it should not be subjected to FDI limits and other restrictions," said a source.
Industry officials have maintained for long that in the current "restrictive regime" no foreign investors would invest in the sector and to make the segment modern and self- dependent, the government should relax the FDI policy.
The sector currently falls under the pharmaceutical category and is accordingly subjected to FDI limits and other conditions, such as the mandatory government approvals.
India allows 100 per cent FDI in the pharma sector. While FDI is permitted through automatic route in case of greenfield investment or new venture, Foreign Investment Promotion Board (FIPB) approval is required in case of brownfield or existing companies. Besides, there are many other riders.
As per estimates, India imports about 70 per cent of its requirement of medical devices. The industry size is about USD 7 billion in the country.
Medical devices include wide range of products such as sutures, implants and surgical instruments.
After a spate of mergers mergers and acquisition of big domestic pharma companies by multi-national firms, government tightened the FDI policy for the sector.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Oct 12 2014 | 10:39 AM IST

Next Story